WHS AMR Roundtable
On the 23rd September, we teamed up with Roche and the Fleming Initiative to host a closed high-level AMR roundtable on the sidelines of World Health Summit 2025.
The discussion focused on turning the 2024 Political Declaration on AMR into real action โ ensuring new antibiotics are valued not only for sales, but also for their public health and societal impact.
๐๐ ๐ก๐๐ฏ๐ 193 ๐๐จ๐ฎ๐ง๐ญ๐ซ๐ข๐๐ฌ ๐ญ๐ก๐๐ญ ๐ก๐๐ฏ๐ ๐๐ ๐ซ๐๐๐ ๐ญ๐จ ๐ญ๐๐ค๐ ๐๐๐ญ๐ข๐จ๐ง ๐จ๐ง ๐๐๐ โ ๐ญ๐ก๐ ๐ช๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง ๐ง๐จ๐ฐ ๐ข๐ฌ โ ๐ฐ๐ก๐๐ญ ๐๐ซ๐ ๐ฐ๐ ๐ ๐จ๐ข๐ง๐ ๐ญ๐จ ๐๐จ ๐๐ข๐๐๐๐ซ๐๐ง๐ญ๐ฅ๐ฒ?
๐๐๐ซ๐ ๐๐ซ๐ ๐จ๐ฎ๐ซ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ ๐๐๐๐ญ๐ข๐ง๐ :
1๏ธโฃ ๐๐๐๐จ๐ ๐ง๐ข๐ณ๐ ๐๐ซ๐จ๐ ๐ซ๐๐ฌ๐ฌ โ ๐๐ง๐ ๐๐๐๐ฉ ๐๐จ๐ข๐ง๐
From the 2024 Political Declaration on AMR to ongoing efforts to create the Independent Panel on Evidence for Action Against AMR, thereโs much to celebrateโbut more still to do. The key task now is: how can we turn these efforts into measurable targets and real impact?
2๏ธโฃ ๐๐ฎ๐ข๐ฅ๐ ๐๐จ๐ง๐ฌ๐๐ง๐ฌ๐ฎ๐ฌ ๐ญ๐จ ๐๐ซ๐ข๐ฏ๐ ๐๐ฎ๐ฅ๐ฅ-๐๐ง๐๐๐ง๐ญ๐ข๐ฏ๐๐ฌ
Pull-incentives are crucial tools to support the development of new antibiotics. Now we have proven examples, we need agreement on sustainable targets and ways of encouraging broader implementation.
3๏ธโฃ ๐๐จ ๐๐๐ฒ๐จ๐ง๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐๐ฌ๐ฌ๐๐ฌ๐ฌ๐ฆ๐๐ง๐ญ๐ฌ (๐๐๐๐ฌ)
HTAs have been helpful for assessing a drugโs value for individual patients โ but few fully capture broader societal and public health impacts, like saving cancer patientsโ lives from infections. Experiences from G7 countries can offer useful guidance.
4๏ธโฃ ๐๐ง๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ ๐ญ๐ก๐ ๐๐๐จ๐ง๐จ๐ฆ๐ข๐๐ฌ ๐จ๐ ๐๐ญ๐๐ฐ๐๐ซ๐๐ฌ๐ก๐ข๐ฉ
Often, One Health stakeholders are missing from key conversations โ yet prevention starts with them. Programs that strengthen animal and environmental health emphasizing sanitation and vaccinationโ can reduce the need for costly antibiotics. They also make investing in new antibiotics and diagnostics less risky. Thatโs why a One Health approach is essential.
5๏ธโฃ ๐๐ญ๐ข๐ฅ๐ฅ ๐๐จ๐ซ๐ ๐ญ๐จ ๐๐จ ๐๐จ๐ฌ๐ญ-๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ฅ
Structural barriers โ such as weak logistics, too few trained AMR healthcare professionals, country-by-country uptake, and demand forecasting โ prevent manufacturers from scalingย โย and keep drugs from reaching patients in need.
Thank you to all our partners and colleagues for driving these critical discussions and keeping AMR high on the global health agenda.
Phot credit: World Health Summit
